Dr Reddy’s Q2 profit falls 36%, plans semaglutide relaunch in November
Mint

Lower US sales of generic Revlimid dragged down second-quarter earnings, but double-digit growth in base markets and the upcoming relaunch of semaglutide offer near-term relief.
Summary from Mint
Read the full story on MintFollow







